About
Profile
At Gilead we are inspired by the opportunity to address unmet medical needs for patients living with life-threatening diseases around the world.
Headquarters
Intraday
High
-
Low
-
52-week
High
-
Low
-
GILD
Shares of the bio-pharmaceutical company added about 2% after surpassing Wall Street esitmates for its full-year earnings guidance. Gilead now forecasts earnings per share in the range of $4.25 to $4.45 per share, while analysts polled by LSEG were looking for $3.80.
...
Available for logged in users only.
The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.
Contact us via Twitter if you are interested in trying it out.
- Gilead Sciences Non-GAAP EPS of $1.72 misses by $0.04, revenue of $7.12B beats by $20M
- Gilead set to roll out Q4 results post-market Tuesday
- Gilead Sciences stock traded in the red for seventh straight session
- Earnings week ahead: Alibaba, PepsiCo, Disney, Palantir, McDonalds, Ford and more
- Arcus Biosciences: Did Gilead Sciences overpay for its latest investment?
- Gilead gets FDA okay for faster Yescarta production process
- Arcus shares extend gains amid mixed reactions on Gilead stake purchase
- Gilead invests $320M in Arcus, expands stake to 33%
- Big Pharma earnings season in spotlight amid positive sentiment
- PBMs ramp up lobbying efforts amid growing public scrutiny
- Gilead stands behind benefits of its CAR-T therapies
- CAR-T therapies to get boxed warning on blood cancer risk
- Gilead in selloff after late-stage setback for Trodelvy
- Biggest stock movers today: Boeing, NuStar Energy, Archer-Daniels-Midland, and more
- Gilead stock drops as Trodelvy fails Phase 3 lung cancer trial
- Eli Lilly’s Jaypirca to lead BTK inhibitor market for leukemia
- Arcus posts early-stage data for Gilead-partnered cancer therapy
- First RSV shots, groundbreaking gene therapy among 2024 drugs to watch
- Health stocks to watch this earnings season as sector poised for resurgence
- Gilead must face negligence claims over HIV drug development, court says
| Date | Price | Open | High | Low | Vol | Change | |||
|---|---|---|---|---|---|---|---|---|---|
| Nov 20 | 88.63 | 88.11 |
89.07
|
87.78
|
4.3M | 1% | |||
| Nov 19 | 87.75 | 87.63 |
88.6
|
86.08
|
8.2M | -0.8% | |||
| Nov 18 | 88.46 | 88.39 |
89.04
|
87.63
|
9.1M | 0.07% | |||
| Nov 15 | 88.4 | 91.71 |
91.99
|
88.21
|
11.5M | -4.03% | |||
| Nov 14 | 92.11 | 92.31 |
92.66
|
91.29
|
8.2M | -0.56% | |||
| Nov 13 | 92.63 | 94.13 |
94.21
|
91.63
|
11.1M | -1.82% | |||
| Nov 12 | 94.35 | 96.35 |
96.84
|
94.22
|
9.3M | -2.76% | |||
| Nov 11 | 97.03 | 96.4 |
98.9
|
96.3
|
7.1M | 0.48% | |||
| Nov 8 | 96.57 | 96.05 |
97.32
|
94.91
|
7.5M | -1.36% | |||
| Nov 7 | 97.9 | 94 |
98.32
|
93.51
|
14.4M | 6.77% | |||
| Nov 6 | 91.69 | 91 |
91.98
|
90.5
|
8.8M | 1.63% | |||
| Nov 5 | 90.22 | 89.64 |
90.39
|
89.01
|
4.0M | 0.42% | |||
| Nov 4 | 89.84 | 89.49 |
90.71
|
89.37
|
6.1M | 0.37% | |||
| Nov 1 | 89.51 | 88.31 |
89.57
|
88.19
|
6.5M | 0.78% | |||
| Oct 31 | 88.82 | 87.94 |
89.28
|
87.74
|
5.9M | 0.60% | |||
| Oct 30 | 88.29 | 87.9 |
88.37
|
87.48
|
5.8M | 0.24% | |||
| Oct 29 | 88.08 | 88.38 |
88.52
|
86.81
|
6.7M | -0.77% | |||
| Oct 28 | 88.76 | 89.24 |
89.42
|
88.52
|
6.0M | -0.27% | |||
| Oct 25 | 89 | 89.45 |
89.74
|
88.45
|
5.7M | 0.25% | |||
| Oct 24 | 88.78 | 87.72 |
89.21
|
87.61
|
7.2M | 1.78% | |||
| Oct 23 | 87.23 | 88.15 |
88.39
|
87.14
|
4.4M | -1.05% | |||
| Oct 22 | 88.16 | 85.68 |
88.36
|
85.6
|
6.0M | 2.17% | |||
| Oct 21 | 86.29 | 86.64 |
87.27
|
85.92
|
4.5M | -0.5% | |||
| Oct 18 | 86.72 | 86.79 |
87.17
|
86.01
|
4.4M | -0.73% | |||
| Oct 17 | 87.36 | 86.92 |
87.65
|
86.59
|
4.3M | 0.70% | |||
| Oct 16 | 86.75 | 85.83 |
86.82
|
85.82
|
3.2M | 1.08% | |||
| Oct 15 | 85.82 | 85.18 |
86.64
|
84.8
|
5.1M | 0.91% | |||
| Oct 14 | 85.05 | 84.92 |
85.34
|
84.34
|
3.5M | 0.12% | |||
| Oct 11 | 84.95 | 84.86 |
84.97
|
84.17
|
4.0M | 0.33% | |||
| Oct 10 | 84.67 | 85.83 |
85.94
|
84.59
|
3.8M | -1.71% | |||
| Oct 9 | 86.14 | 85.18 |
86.85
|
85.06
|
6.2M | 1.09% | |||
| Oct 8 | 85.21 | 84.52 |
85.39
|
84.32
|
4.6M | 0.92% | |||
| Oct 7 | 84.43 | 85.05 |
85.66
|
84.34
|
4.7M | -0.19% | |||
| Oct 4 | 84.59 | 84.34 |
84.96
|
83.98
|
4.1M | 0.50% | |||
| Oct 3 | 84.17 | 84.25 |
84.93
|
84.01
|
4.1M | -0.67% | |||
| Oct 2 | 84.74 | 83.33 |
85.43
|
83.1
|
6.0M | 0.95% | |||
| Oct 1 | 83.94 | 83.82 |
83.98
|
82.82
|
6.6M | 0.12% | |||
| Sep 30 | 83.84 | 83.15 |
84.25
|
83.14
|
5.1M | 0.28% | |||
| Sep 27 | 83.61 | 83.23 |
84.33
|
83.04
|
5.5M | 0.69% | |||
| Sep 26 | 83.04 | 82.02 |
83.12
|
81.83
|
5.7M | 1.01% | |||
| Sep 25 | 82.21 | 83.93 |
83.99
|
82.15
|
8.4M | -1.89% | |||
| Sep 24 | 83.79 | 83.79 |
84.28
|
83.34
|
8.0M | -0.24% | |||
| Sep 23 | 83.99 | 84.25 |
84.46
|
83.48
|
6.5M | 0.06% | |||
| Sep 20 | 83.94 | 83.26 |
83.99
|
82.75
|
24.9M | 0.05% | |||
| Sep 19 | 83.9 | 84.39 |
84.65
|
83.43
|
8.8M | 0.01% | |||
| Sep 18 | 83.89 | 83.37 |
84.52
|
82.76
|
9.2M | 1.01% | |||
| Sep 17 | 83.05 | 83.06 |
83.33
|
82.38
|
7.1M | -0.13% | |||
| Sep 16 | 83.16 | 83 |
83.58
|
82.52
|
7.8M | 0.42% | |||
| Sep 13 | 82.81 | 81.95 |
83.17
|
81.57
|
6.5M | -0.42% | |||
| Sep 12 | 83.16 | 83.02 |
84.89
|
81.98
|
11.5M | 2.74% | |||
| Sep 11 | 80.94 | 81.14 |
81.2
|
79.64
|
6.1M | -0.61% | |||
| Sep 10 | 81.44 | 79.17 |
81.56
|
78.73
|
6.9M | 2.87% | |||
| Sep 9 | 79.17 | 78.4 |
80.2
|
78.36
|
5.6M | 0.57% | |||
| Sep 6 | 78.72 | 79.11 |
79.21
|
78.26
|
9.2M | -0.06% | |||
| Sep 5 | 78.77 | 78.95 |
79.32
|
77.74
|
4.3M | -0.45% | |||
| Sep 4 | 79.13 | 79.67 |
80
|
78.72
|
4.6M | -0.72% | |||
| Sep 3 | 79.7 | 79.79 |
80.43
|
79.4
|
8.7M | 0.89% | |||
| Aug 30 | 79 | 79.43 |
80.25
|
78.6
|
6.2M | -0.57% | |||
| Aug 29 | 79.45 | 78.93 |
79.65
|
78.25
|
5.5M | 1.13% | |||
| Aug 28 | 78.56 | 77.46 |
79.45
|
77.23
|
6.2M | 0% | |||